WUHAN, China, Aug. 13, 2025 /PRNewswire/ -- China Automotive Systems, Inc. (NASDAQ: CAAS) ("CAAS" or the "Company"), a leading power steering components and systems supplier in...
– Total Revenues increased 13.8% for the quarter over the prior year period to $60.3 million – – Total Written Premium increased 14.4% for the quarter over the prior year period to $450.3 million – – Organic Revenue Growth Rate* of 10.6% for the quarter – – Net income of $9.0 million for the quarter – – Adjusted EBITDA* increased 40.7% for the quarter over the prior year period to $15.1 million –
TSX: MPVD
TORONTO, Aug. 12, 2025 /PRNewswire/ - Mountain Province Diamonds Inc. ("Mountain Province", the "Company") (TSX: MPVD) today announces financial results for the second quarter...
TSX: MPVD
TORONTO, Aug. 12, 2025 /PRNewswire/ -- Mountain Province Diamonds Inc. ("Mountain Province", the "Company") (TSX: MPVD) today announces financial results for the second quarter...
TSX: MPVD
TORONTO, Aug. 12, 2025 /CNW/ - Mountain Province Diamonds Inc. ("Mountain Province", the "Company") (TSX: MPVD) today announces financial results for the second quarter...
BIRMINGHAM, Mich., Aug. 12, 2025 /PRNewswire/ -- OneStream, Inc. (Nasdaq: OS), the leading enterprise Finance management platform that modernizes the Office of the CFO...
VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.
• First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026
MARKHAM, Ontario, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced its financial results for the three and six months ended June 30, 2025.
WOODLAND PARK, N.J., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Anterix (NASDAQ: ATEX) today announced its first quarter fiscal 2026 results and filed its Form 10-Q for the three months ended June 30, 2025. The Company also issued an update on its Demonstrated Intent metric which can be found on Anterix’s website at https://investors.anterix.com/events-presentations.
YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1Pivotal Phase 3 CYPRESS study enrollment on track to complete by late...
IRVING, Texas, Aug. 12, 2025 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient-centric, next-generation AI TechBio company, today reported financial results...